415 related articles for article (PubMed ID: 27113410)
21. Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
Gupta A; Saltarski JM; White MA; Scaglioni PP; Gerber DE
J Thorac Oncol; 2017 Sep; 12(9):1446-1450. PubMed ID: 28647672
[TBL] [Abstract][Full Text] [Related]
22. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
23. Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection.
Lu C; Figueroa JA; Liu Z; Konala V; Aulakh A; Verma R; Cobos E; Chiriva-Internati M; Gao W
Curr Cancer Drug Targets; 2015; 15(7):575-92. PubMed ID: 26324128
[TBL] [Abstract][Full Text] [Related]
24. Both ran and importins have the ability to function as nuclear mRNA export factors.
Yi R; Bogerd HP; Wiegand HL; Cullen BR
RNA; 2002 Feb; 8(2):180-7. PubMed ID: 11911364
[TBL] [Abstract][Full Text] [Related]
25. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.
Ranganathan P; Yu X; Santhanam R; Hofstetter J; Walker A; Walsh K; Bhatnagar B; Klisovic R; Vasu S; Phelps MA; Devine S; Shacham S; Kauffman M; Marcucci G; Blum W; Garzon R
Blood; 2015 Apr; 125(17):2689-92. PubMed ID: 25716206
[TBL] [Abstract][Full Text] [Related]
26. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Turner JG; Cui Y; Bauer AA; Dawson JL; Gomez JA; Kim J; Cubitt CL; Nishihori T; Dalton WS; Sullivan DM
Cancer Res; 2020 Dec; 80(23):5344-5354. PubMed ID: 33023948
[TBL] [Abstract][Full Text] [Related]
27. Xpo7 is a broad-spectrum exportin and a nuclear import receptor.
Aksu M; Pleiner T; Karaca S; Kappert C; Dehne HJ; Seibel K; Urlaub H; Bohnsack MT; Görlich D
J Cell Biol; 2018 Jul; 217(7):2329-2340. PubMed ID: 29748336
[TBL] [Abstract][Full Text] [Related]
28. Nuclear entrapment of p33ING1b by inhibition of exportin-1: A trigger of apoptosis in head and neck squamous cell cancer.
Özdaş S
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):66-72. PubMed ID: 29729696
[TBL] [Abstract][Full Text] [Related]
29. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
Lai C; Xu L; Dai S
Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
[TBL] [Abstract][Full Text] [Related]
30. Atomic basis of CRM1-cargo recognition, release and inhibition.
Fung HY; Chook YM
Semin Cancer Biol; 2014 Aug; 27():52-61. PubMed ID: 24631835
[TBL] [Abstract][Full Text] [Related]
31. Importins and exportins in cellular differentiation.
Okada N; Ishigami Y; Suzuki T; Kaneko A; Yasui K; Fukutomi R; Isemura M
J Cell Mol Med; 2008 Oct; 12(5B):1863-71. PubMed ID: 18657223
[TBL] [Abstract][Full Text] [Related]
32. Ran-dependent nuclear export mediators: a structural perspective.
Güttler T; Görlich D
EMBO J; 2011 Aug; 30(17):3457-74. PubMed ID: 21878989
[TBL] [Abstract][Full Text] [Related]
33. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
34. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
35. Importin-beta-like nuclear transport receptors.
Ström AC; Weis K
Genome Biol; 2001; 2(6):REVIEWS3008. PubMed ID: 11423015
[TBL] [Abstract][Full Text] [Related]
36. Allosteric control of the exportin CRM1 unraveled by crystal structure analysis.
Monecke T; Dickmanns A; Ficner R
FEBS J; 2014 Sep; 281(18):4179-94. PubMed ID: 24823279
[TBL] [Abstract][Full Text] [Related]
37. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
38. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract][Full Text] [Related]
39. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.
Pathria G; Wagner C; Wagner SN
J Invest Dermatol; 2012 Dec; 132(12):2780-90. PubMed ID: 22832492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
